Saudi Arabia Continuous Glucose Monitoring Market size to cross USD 344.2 Million by 2034

Selbyville, DE. - Saudi Arabia continuous glucose monitoring market was estimated at USD 92.2 million in 2024 and is expected to grow from USD 104.2 million in 2025 to USD 344.2 million by 2034, at a CAGR of 16.1%, according to the latest report published by Global Market Insights Inc.  

Saudi Arabia has one of the highest diabetes prevalence rates globally, with Type 2 diabetes affecting a significant portion of the adult population. This growing burden is driving strong demand for effective glucose monitoring tools, making CGM systems a critical component in diabetes management.  

Key Insights:

Market Size & Growth:

• 2024 Market Size: USD 92.9 million
• 2025 Market Size: USD 104.2 million
• 2034 Forecast Market Size: USD 344.2 million
• CAGR (2025–2034): 16.1%  

Key Growth Drivers:

1. Government initiatives to improve diabetes care: The Saudi government is actively promoting chronic disease management through national health campaigns and investment in digital health infrastructure.  
2. Rising awareness and patient education: Increased public awareness about the benefits of continuous glucose monitoring, such as real-time data, fewer finger pricks, and better glycemic control, is encouraging patients to shift from traditional methods to advanced CGM devices.  
3. Growth in tech-savvy, health-conscious population: Saudi Arabia's relatively young, tech-adaptive population is more open to wearable health technology.  
4. Improved access to advanced medical devices: Saudi Arabia is witnessing a steady expansion of its medical technology sector, with increased availability of FDA- and CE-approved CGM systems.  
5. Expansion of private healthcare and insurance coverage: The growing private healthcare sector, along with expanding health insurance coverage, is making CGM systems more accessible and affordable to a broader patient base.  

Key Players:

• Abbott Laboratories led the market with over 59.3% share in 2024.  
• Some of the top players in this market include Medtronic, Abbott Laboratories, Sinocare, Dexcom, and MedTrust, which together held a 98% share in 2024.  

Key Challenges

1. High cost of devices and limited reimbursement: Despite growing demand, the high price of CGM systems remains a significant barrier for many patients in Saudi Arabia.  
2. Lack of awareness and education among patients and healthcare providers: While awareness is improving, many patients and some healthcare professionals still lack sufficient knowledge about the benefits and proper use of CGM technology.  
3. Cultural and behavioral resistance to wearable technology: In some segments of the Saudi population, cultural attitudes and behavioral reluctance towards wearing continuous monitoring devices can impede market growth.  
4. Limited availability of trained specialists: Effective use of CGM devices often requires professional guidance for the interpretation and management of glucose data.  
5. Regulatory and distribution challenges: Though regulatory frameworks are evolving, delays in device approvals and challenges in establishing efficient distribution channels can slow the market introduction of new CGM technologies, impacting accessibility and choice for patients.  

Browse key industry insights spread across 65 pages with 39 market data tables and figures from the report, “Saudi Arabia Continuous Glucose Monitoring Market Size - By Component, By End Use - Forecast, 2025 - 2034” in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/saudi-arabia-continuous-glucose-monitoring-market  

Growing Adoption of CGM Sensors

The sensors segment in the Saudi Arabia continuous glucose monitoring market accounted for a significant share in 2024. These sensors are essential for capturing real-time glucose levels from interstitial fluid and transmitting accurate data to devices or smartphone applications. As users seek enhanced comfort, longer wear duration, and minimal calibration requirements, manufacturers are focusing on advancing sensor technology. Innovations such as extended wear sensors, flexible materials, and pre-calibrated solutions are fueling this segment’s expansion. The upward trend underscores a broader movement toward user convenience, particularly for individuals managing diabetes outside of traditional healthcare facilities.  

Increasing shifts toward home care settings

The home care segment is expected to experience steady growth between 2025 and 2034, driven by a rising preference for remote monitoring and self-managed care. Patients are increasingly turning to CGM systems to track glucose levels in real time from the comfort of their homes. These systems not only support daily disease management but also enable seamless data sharing with healthcare providers and family members through connected digital platforms. This trend is minimizing the need for frequent clinical visits and empowering individuals to take a more proactive and independent role in their diabetes care.  

Major players in the Saudi Arabia continuous glucose monitoring market are MedTrust, Abbott Laboratories, Sinocare, Dexcom, A. Menarini Diagnostics, and Medtronic.  

To strengthen their presence in the Saudi Arabia Continuous Glucose Monitoring (CGM) market, leading companies are focusing on a mix of local partnerships, awareness campaigns, product localization, and regulatory engagement. Collaborations with healthcare providers, clinics, and diabetes centers are helping manufacturers improve device accessibility and build trust among patients. Firms are also investing in public and physician education programs to increase awareness about the clinical benefits of CGM over traditional glucose monitoring methods.  

Additionally, companies are working with regulatory authorities to accelerate device approvals and align with Saudi FDA standards. Localization strategies, including Arabic-language interfaces and region-specific app features, are being used to enhance user engagement. Furthermore, insurance collaboration efforts are underway to expand reimbursement coverage, making CGM technology more affordable and appealing to a broader patient base.